Edgewise Therapeutics/$EWTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Ticker
$EWTX
Sector
Primary listing
Employees
146
Headquarters
Website
EWTX Metrics
BasicAdvanced
$3.6B
-
-$1.63
0.26
-
Price and volume
Market cap
$3.6B
Beta
0.26
52-week high
$33.56
52-week low
$10.60
Average daily volume
906K
Financial strength
Current ratio
19.853
Quick ratio
19.368
Long term debt to equity
0.57
Total debt to equity
0.764
Profitability
EBITDA (TTM)
-189.322
Management effectiveness
Return on assets (TTM)
-23.02%
Return on equity (TTM)
-34.19%
Valuation
Price to book
6.78
Price to tangible book (TTM)
6.78
Price to free cash flow (TTM)
-23.812
Free cash flow yield (TTM)
-4.20%
Free cash flow per share (TTM)
-1.4
Growth
Earnings per share change (TTM)
12.58%
3-year earnings per share growth (CAGR)
8.91%
What the Analysts think about EWTX
Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.
EWTX Financial Performance
Revenues and expenses
EWTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edgewise Therapeutics stock?
Edgewise Therapeutics (EWTX) has a market cap of $3.6B as of April 07, 2026.
What is the P/E ratio for Edgewise Therapeutics stock?
The price to earnings (P/E) ratio for Edgewise Therapeutics (EWTX) stock is 0 as of April 07, 2026.
Does Edgewise Therapeutics stock pay dividends?
No, Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders as of April 07, 2026.
When is the next Edgewise Therapeutics dividend payment date?
Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Edgewise Therapeutics?
Edgewise Therapeutics (EWTX) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.